IRIS
MUSTO, Pellegrino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.970
EU - Europa 1.363
AS - Asia 414
AF - Africa 2
SA - Sud America 2
OC - Oceania 1
Totale 7.752
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.968
SE - Svezia 542
IT - Italia 286
CN - Cina 274
GB - Regno Unito 184
FR - Francia 118
DE - Germania 114
SG - Singapore 69
IE - Irlanda 26
FI - Finlandia 23
HK - Hong Kong 23
RU - Federazione Russa 23
UA - Ucraina 19
VN - Vietnam 14
IN - India 13
BE - Belgio 9
CZ - Repubblica Ceca 9
TR - Turchia 5
NL - Olanda 4
TW - Taiwan 4
JP - Giappone 3
KR - Corea 3
PL - Polonia 3
TH - Thailandia 2
AL - Albania 1
AR - Argentina 1
BR - Brasile 1
CA - Canada 1
DO - Repubblica Dominicana 1
ES - Italia 1
ID - Indonesia 1
IL - Israele 1
IR - Iran 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
UG - Uganda 1
Totale 7.752
Salva come PNG Salva come JPEG
Città #
Fairfield 1.075
Nyköping 457
New York 407
Chandler 397
Woodbridge 393
Ashburn 357
Houston 344
Lawrence 343
Cambridge 338
Seattle 330
Wilmington 289
Roxbury 284
Des Moines 236
Ann Arbor 217
San Diego 126
Paris 107
Princeton 78
London 57
Bari 48
Matera 48
Inglewood 44
Singapore 43
Jacksonville 41
Boardman 35
Beijing 33
Potenza 31
Nanjing 27
Dublin 26
Guangzhou 20
Kilburn 20
Shanghai 20
Hounslow 19
Norwalk 18
Rome 16
Los Angeles 15
Avigliano 14
Dong Ket 14
Chiswick 12
Jiaxing 12
Shenyang 11
Wuhan 11
Brooklyn 9
Brussels 9
Prescot 9
Hanover 8
Imbersago 8
New Bedfont 8
Brno 7
Dearborn 7
Munich 7
Marseille 6
Nanchang 6
Bitetto 5
Hong Kong 5
Milan 5
Modugno 5
Shenzhen 5
Southwark 5
Torino 5
Washington 5
Alcamo 4
Bitonto 4
Chicago 4
Florence 4
Messina 4
Pune 4
Quanzhou 4
Tianjin 4
West Jordan 4
Wuxi 4
Acton 3
Bisceglie 3
Böblingen 3
Esslingen am Neckar 3
Helsinki 3
Islington 3
Istanbul 3
Jinhua 3
Suri 3
Verona 3
Wandsworth 3
Zhengzhou 3
Bengaluru 2
Changsha 2
Chiang Mai 2
Fragagnano 2
Frankfurt am Main 2
Gatchina 2
Hangzhou 2
Hebei 2
Itri 2
Kobe 2
Liveri 2
Marsala 2
Molfetta 2
Moscow 2
Mumbai 2
Nagold 2
Nuremberg 2
Olomouc 2
Totale 6.649
Salva come PNG Salva come JPEG
Nome #
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets 117
Differences among young adults, adults, and elderly chronic myeloid leukemia patients. 110
null 101
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 100
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 97
Amyloid in bone marrow smears of patients affected by multiple myeloma 96
Cardiovascular events and intensity of treatment in polycythemia vera. 93
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 92
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 89
null 85
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 84
null 82
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 81
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response 81
FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. 80
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 79
Global methylation patterns in primary plasma cell leukemia 79
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 77
null 75
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 75
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 73
null 71
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 71
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 70
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study) 68
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma 68
90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma 65
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 64
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial 62
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival 54
Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients 48
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 47
null 46
Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma 46
RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia 45
Inflammatory Cells in Diffuse Large B Cell Lymphoma 44
Epitranscriptomics in normal and malignant hematopoiesis 42
Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells 41
Bortezomib and zoledornic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma 40
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 40
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project 37
Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia 36
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 36
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity 36
Achievement of European standards by CROB-IRCCS 36
F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma 34
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. 34
After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia 34
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 33
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 33
Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia 32
Analysis of amount, size, protein phenotype and molecular content of circulating extracellular vesicles identifies new biomarkers in multiple myeloma 32
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: A pooled analysis of two studies 32
Myeloma cells regulate {miRNA} transfer from fibroblast-derived exosomes by expression of {lncRNAs} 32
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 31
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 31
What Is New in the Treatment of Smoldering Multiple Myeloma? 31
Acquired hemophilia a successfully treated with rituximab 31
90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma 31
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia 31
Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study 31
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 31
The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells 31
A pilot characterization of human lung NSCLC by protein pathway activation mapping 30
CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results 30
IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis 30
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study 29
Advanced mast cell disease: an Italian Hematological Multicenter experience 29
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 29
Can the new and old drugs exert an immunomodulatory effect in acute myeloid leukemia? 28
Superiority of droplet digital PCR over real-time quantitative PCR for JAK2 V617F allele mutational burden assessment in myeloproliferative neoplasms: A retrospective study 28
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach. 28
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice 28
Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant 28
null 28
P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome 27
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches 27
Melphalan 200 mg/m2 versus Melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multi-center phase III study 26
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 26
P138 Valproic acid at therapeutic plasma levels may increase 5-azacitidine efficacy in higher risk myelodysplastic syndromes 26
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 26
Meningeal Involvement in Primary Plasma Cell Leukemia 26
Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link? 25
Gastric normal adjacent mucosa versus healthy and cancer tissues: Distinctive transcriptomic profiles and biological features 25
Future in the past: Azorella glabra wedd. as a source of new natural compounds with antiproliferative and cytotoxic activity on multiple myeloma cells 25
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 24
Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation? 24
Primary Plasma Cell Leukemia: Identity Card 2016 24
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 24
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma 23
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 23
Acute promyelocytic leukemia in patients aged over 60 years: multicenter experience of 34 consecutive unselected patients 23
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program 23
An update on biology, diagnosis and treatment of primary plasma cell leukemia 23
New treatment strategies for elderly myeloma patients 23
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 23
Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia 23
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 22
Tumor cell microenvironment and microvessel density analysis in MALT type lymphoma 22
The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation 22
Totale 4.584
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.588
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.588
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020629 0 39 22 85 81 52 64 80 98 38 38 32
2020/20211.463 19 42 17 38 71 53 46 62 23 67 984 41
2021/20222.512 539 283 17 36 22 292 110 85 244 199 289 396
2022/20231.729 405 237 143 66 102 194 111 144 235 18 46 28
2023/20241.201 97 141 78 56 102 462 58 28 2 14 22 141
2024/2025179 161 18 0 0 0 0 0 0 0 0 0 0
Totale 8.292